Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419965 · ClinicalTrials.gov registry record
Measuring G Protein-coupled Receptor Kinase-2 (GRK2) in the Blood to Diagnose and Treat Patients With Heart Failure
A clinical trial, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- 582
- Enrollment target
NCT00419965: Completed study, sponsored by Thomas Jefferson University.
NCT00419965 is a clinical trial that has completed, run by Thomas Jefferson University. The registered enrollment target is 582 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00419965 has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- 582 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the utility of GRK2 to differentiate between normal patients and patient groups that differ by the presence/absence of HF symptoms, systolic or diastolic left ventricular dysfunction, and risk factors; and to evaluate if a new assay provides similar values as traditional methods for measuring GRK2 levels.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 582 participants |
| Start Date | 2006-10 |
| Est. Completion | 2010-05 |
What the finished NCT00419965 record still lists
NCT00419965 is an observational study that tracks outcomes without assigning an intervention. The registered 582 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00419965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00419965 about?
NCT00419965 is a clinical study titled "Measuring G Protein-coupled Receptor Kinase-2 (GRK2) in the Blood to Diagnose and Treat Patients With Heart Failure". The primary objective of this study is to determine the utility of GRK2 to differentiate between normal patients and patient groups that differ by the presence/absence of HF symptoms, systolic or diastolic left ventricular dysfunction, and risk factors; and to evaluate if a new assay provides simila...
What is the current status of trial NCT00419965?
This trial is currently completed. The enrollment target is 582 participants. The study started on 2006-10. Estimated completion is 2010-05.
Who is sponsoring clinical trial NCT00419965?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06350097 · 582 participants · Phase 3
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- NCT06563895 · 582 participants · Phase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- NCT06819007 · 582 participants · Phase 3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- NCT03840083 · 584 participants · NA
Sleep-dependent Learning in Aging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia